Latest Videos |view all videos
Mayo Clinic electrophysiologist, Paul A. Friedman, M.D., reviews when premature ventricular complexes (PVCs) require further evaluation, the type of evaluation required and when treatment is necessary.
Steve R. Ommen, M.D., director, Hypertrophic Cardiomyopathy Clinic at Mayo Clinic, discusses management of symptoms in people with hypertrophic cardiomyopathy, as well as assessment of risk of sudden cardiac death.
Steve R. Ommen, M.D., director, Hypertrophic Cardiomyopathy Clinic at Mayo Clinic, reviews risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy.
Steve R. Ommen, M.D., reviews management of symptoms in patients with obstructive hypertrophic cardiomyopathy and treatment options, including lifestyle behaviors, medical management, and more-invasive options such as myectomy or ablation.
Joseph A. Dearani, M.D., chair, Cardiovascular Surgery at Mayo Clinic, discusses shared medical decision-making for patients considering a heart valve intervention.
Mayo Clinic cardiologist and sleep expert, Virend Somers, M.D., Ph.D., discusses sleep apnea and its impact on the cardiovascular system as well as treatment options.
Mayo Clinic hematologist Angela Dispenzieri, M.D., discusses immunoglobulin light chain amyloidosis — also called AL amyloidosis — treatment, including high-dose chemotherapy with stem cell transplantation.
Mayo Clinic physicians, Robert D. McBane II, M.D., (cardiology) and Ariela Marshall, M.D., (hematology), discuss the new Food and Drug Administration (FDA) drug watch list, specifically the direct-acting oral anticoagulants (DOACs).
Mayo Clinic hematologist, Angela Dispenzieri, M.D., discusses liver transplant for transthyretin amyloidosis.